| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.055 | 0.07 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.07 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.082 | 0.07 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.07 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | 0.056 | 0.07 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.07 |